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Abstract
Background: Inflammation is associated with poor outcome after stroke. A relationship between ex vivo cytokine
synthesis and stroke outcome remains unclear. We explored an association between ex vivo cytokine release,
circulating interleukin (IL)-6 as a marker of systemic inflammation, and stroke prognosis. We assessed the utility of
ex vivo synthesized cytokines for predicting stroke outcome.
Methods: We collected blood from 248 ischemic stroke patients and stimulated it ex vivo with lipopolysaccharide.
We measured concentration of synthesized cytokines (TNFα, IP-10, IL-1β, IL-6, IL-8, IL-10, and IL-12) and plasma IL-6.
We assessed functional outcome 3 months after stroke using the modified Rankin Scale. To assess the prognostic
ability of cytokines, we applied multivariate logistic regression, cluster analysis, and construction of multimarker
score.
Results: Decreased release of IP-10, TNFα, IL-1β, and IL-12; increased release of IL-10 and IL-8; and higher plasma IL-
6 level were associated with poor outcome. Cluster analysis identified three groups of patients with distinct
cytokine profiles. The group with the worst outcome demonstrated high synthesis of IL-10, IL-8, IL-1β, and IL-6 and
low synthesis of IL-12, IP-10, and TNFα accompanied by high circulating IL-6 level. The group with the best
prognosis showed high synthesis of TNFα, IP-10, IL-12, IL-1β, and IL-6; low synthesis of IL-10 and IL-8; and low
plasma IL-6. Patients with intermediate outcome had low synthesis of all cytokines accompanied by low circulating
IL-6. We constructed a multimarker score composed of ex vivo released IL-12, IL-10, TNFα, and plasma IL-6. Addition
of this score to clinical variables led to significant increase in c-statistic (0.81 vs 0.73, p = 0.02) and net
reclassification improvement.
Conclusion: The decreased ex vivo release of pro-inflammatory cytokines and increased release of IL-10 and IL-8
are related to poor outcome after stroke. Cytokine-based multimarker score adds prognostic value to clinical model
for predicting stroke outcome.
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Background
Acute ischemic stroke is accompanied by both immuno-
depression and systemic inflammation [1, 2]. Post-stroke
immunodepression refers to suppression of both innate
and adaptive immune response and is marked by transient
lymphopenia, functional deactivation of monocytes, and
splenic atrophy. At the cytokine level, immunodepression
is reflected in humans by the reduced ex vivo tumor ne-
crosis factor alpha (TNFα) synthesis after whole blood or
monocyte stimulation with endotoxin [3, 4] whereas cir-
culating interleukin-6 (IL-6) is the main cytokine related
to systemic inflammation [5].
Numerous studies showed that elevated blood level of IL-
6 is an independent predictor of poor functional outcome
after stroke [6, 7]. However, the addition of IL-6 to a vali-
dated, clinical-based stroke prognostic model did not im-
prove the prediction of poor outcome. Much less is known
about the prognostic significance of ex vivo cytokine pro-
duction in stroke patients. Few studies suggest that the re-
duced ex vivo TNFα and interferon-gamma-inducible
protein 10 (IP-10) synthesis after endotoxin challenge is as-
sociated with poor functional outcome after stroke [8, 9].
A better understanding of interactions between cyto-
kine synthesis and stroke prognosis is important for at
least two reasons. First, cytokine synthesis could be a po-
tential therapeutic target in acute stroke [10]. Second,
individual cytokines released by blood cells or their com-
bination might serve as a biomarker to stratify risk of
unfavorable outcome after stroke.
In this study, we aimed to explore an association between
ex vivo cytokine synthesis, circulating IL-6 as a marker of
systemic inflammation and stroke prognosis. We also ex-
amined the individual and collective utility of ex vivo syn-
thesized cytokines for predicting stroke outcome.
Methods
Participant and clinical assessment
We prospectively recruited participants from consecutive
stroke patients admitted to the Department of Neurology,
University Hospital in Krakow, Poland, between October
2016 and September 2018. The inclusion criteria were (1)
ischemic stroke, (2) admission within 24 h from symptom
onset, (3) pre-stroke modified Rankin Scale (mRS) score 0–
2, (4) National Institute of Health Stroke Scale (NIHSS)
score on admission >3, and (5) informed consent. We ex-
cluded patients with chronic inflammatory, autoimmune,
or cancerous diseases. Bioethics Committee of Jagiellonian
University approved the study protocol (decision number:
122.6120.249.2016), and each patient gave an informed
consent.
For ischemic stroke diagnosis, we used the updated
definition from the American Heart Association/Ameri-
can Stroke Association [11]. Each patient underwent the
head CT scan on admission. To assess stroke severity on
admission, we used NIHSS score [12]. We used the
TOAST criteria to determine stroke etiology [13]. We
evaluated functional outcome 3months after stroke with
the mRS [14]. We defined poor outcome as a mRS score
3–6.
Laboratory assays
We collected venous blood in heparinised tubes (Sar-
stedt, Germany) at day 3 after stroke onset. To avoid di-
urnal variation in cytokine production, we took blood
between 7.00 and 7.30 am. Subsequently, we diluted the
whole blood by 1:5 in sterile RPMI 1640 medium sup-
plemented with L-glutamine (Sigma Aldrich, St. Louis,
MO, USA) and we stimulated it in sterile tubes (Lonza,
Walkersville, MD, USA) with lipopolysaccharide (LPS
10 ng/mL, E. coli 0111:B4, Sigma Aldrich, St. Louis, MO,
USA) at 37 °C and 5% CO2. Based on previous publica-
tions [9, 15], we stimulated blood for 4 h for TNFα and
IP-10 and 24 h for interleukin IL-1β, IL-6, IL-8, IL-10,
and IL-12p70. We removed supernatants and stored
them at − 80 °C.
To measure concentrations of TNFα and IP-10, we
used commercially available ELISA kits from R&D Sys-
tems (Minneapolis, MN, USA). We measured IL-1β, IL-
6, IL-8, IL-10, and IL-12p70 concentration using a cyto-
metric bead array immunoassay (Human Inflammatory
Kit, BD Bioscience, San Diego, CA, USA). To measure
the level of IL-6 in plasma, we used ELISA kits from
R&D Systems (Minneapolis, MN, USA) with a detection
limit of 0.11 pg/ml.
Statistical analyses
To better understand an association between cytokines
and the poor outcome, we aimed to implement different
statistical approaches.
As a first step, we compared baseline characteristics
and cytokine levels between the group with good out-
come and the group with poor outcome using χ2 test for
proportions and Mann–Whitney U test for continuous
variables. To find independent predictors of outcome,
we performed logistic regression analyses. We standard-
ized cytokines to the same scale (mean = 0, SD = 1) to
facilitate comparison between them. We used univariate
analysis to determine clinical and laboratory predictors.
Then, cytokines with p < 0.05 in the univariate regres-
sion were assessed individually in backward elimination
models adjusted for significant clinical predictors. We
used a retention value of p < 0.05. Finally, we performed
a backward elimination model containing all cytokines
significant in the univariate analysis adjusted for clinical
predictors.
In the second step, we wanted to divide subjects into a
small number of groups with different cytokine concen-
trations and test whether any specific profile could be
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related to the poor outcome. Before clustering, we log
transform cytokines because they were right-skewed and
then we standardize them to the same scale (mean = 0,
SD = 1). To check collinearity between cytokines, we
calculated Pearson’s correlation coefficient and Spear-
man’s rho using a threshold of 0.7 as an indicator of
high collinearity [16]. We grouped patients using ag-
glomerative hierarchical clustering with Ward’s method
of minimum variance and the squared Euclidean dis-
tance metric [17]. We considered this method appropri-
ate for our purposes as it could construct relatively
compact clusters with emphasis on differences between
observations [18]. Clustering was unsupervised and
blinded to outcome. We determined the optimal number
of clusters based on 30 indices provided by NbClust
package in R [19]. To better characterize cytokine pro-
files, we compared clusters with Kruskal-Wallis test
followed by post-hoc Dunn’s test. Next, to determine an
association between clusters and the outcome, we per-
formed uni- and multivariate logistic regressions. The
latter was adjusted for previously identified clinical
predictors.
In the final step, we constructed the multimarker score
to further evaluate the prognostic value of investigated
cytokines. We included cytokines that remained signifi-
cant in the final backward elimination model. The score
was defined as:
Score ¼ βA  cytokineAð Þ þ βB  cytokineBð Þ
þ βC  cytokineC
 
; etc:;
where βA, βB, and βC stand for regression β-
coefficients for cytokines A, B, and C, respectively, from
the backward regression model. We used a model with
two most important predictors of outcome: stroke sever-
ity on admission and age as the best-fit clinical model
[20]. Then, we compared the sole best-fit clinical model
with the best-fit clinical model containing the multimar-
ker score. We also compared the best-fit clinical model
containing the multimarker score with best-fit clinical
models containing individual cytokines. To evaluate the
ability of models to discriminate between good and poor
outcome, we calculated areas under receiver operator
curves (AUC). An AUC of 1 indicates perfect discrimin-
ation and 0.5 no discrimination. We also assessed cali-
bration with the Hosmer-Lemeshow χ2 statistic. Then,
we calculated the integrated discrimination improve-
ment (IDI), a measure of the model to improve average
sensitivity without reducing average specificity [21]. To
assess the ability of the score to reclassify risk, we calcu-
lated net reclassification improvement (NRI) metric [21].
Similarly to the previous study [22], we used clinically
relevant thresholds (< 10%, 10–50%, 50–90%, > 90%) for
the predicted probability of the poor outcome. The
thresholds are based on the assumption that one would
need to be very certain of a good or poor outcome be-
fore avoiding treatment such as thrombolysis or select-
ing patients for palliative care only. We also calculated a
continuous NRI [23].
Statistical analyses were performed in STATA version
14 (StataCorp, College Station, TX) and packages
“NbClust” [17] and “PredictABEL” [24] in R Statistical




We recruited 250 patients into the study. Information
on 3-month functional status was available for 248 pa-
tients, and they were included into further analyses (me-
dian age 69 years, IQs 61–79; 41.1% female; median
NIHSS score 9, IQs 5–17). From the final cohort, 111
participants (44.8%) had a poor 3-month functional out-
come. Table 1 shows comparisons of baseline character-
istics and cytokine levels between the group with good
outcome and the group with poor outcome.
Patients with poor outcome were older and had higher
NIHSS score on admission. They had the increased re-
lease of IL-10 and IL-8 and the decreased release of IL-
12p70, IL-1β, TNFα, and IP-10 after ex vivo stimulation
compared to the group with good outcome. Plasma level
of IL-6 was also higher in the patients with worse
outcome.
In the univariate analysis, older age and higher NIHSS
score on admission were only clinical predictors of poor
outcome (Table 2). Among cytokines, higher release of
IL-10 and IL-8 after ex vivo stimulation as well as higher
plasma level of IL-6 was associated with worse outcome.
In contrast, the higher release of IL-12p70, IL-1β, TNFα,
and IP-10 was related to the decreased risk of poor out-
come. These results remained significant after adjust-
ment for age and stroke severity. However, when we
forced all cytokines into the backward elimination model
adjusted for clinical predictors, only IL-12p70, IL-10,
TNFα, and plasma IL-6 levels remained independent la-
boratory predictors of outcome.
Cluster analysis
We included plasma level of IL-6 and the following
ex vivo produced cytokines: IL-12p70, IL-10, IL-6, IL-8,
IL-1β, TNFα, and IP-10 into cluster analysis. Pearson’s
correlation coefficients or Spearman’s rho between in-
cluded cytokines did not exceed the threshold of 0.7.
We compared different numbers of clusters (maximal
number of 6) based on 30 indices provided by NbClust
package. The three-cluster solution showed the best
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performance (Additional file 1: Figure S1). Cluster charac-
teristics are available in the Additional file 2: Table S1.
In the unsupervised, blinded to outcome analysis, we
obtained three clusters with the different pattern of cyto-
kine concentrations (Fig. 1). Cluster 1 (n = 68) had rela-
tively high release of IL-12p70, TNFα, IP-10, IL-6, and
IL-1β; low synthesis of IL-10 and IL-8; and low level of
plasma IL-6. Cluster 2 (n = 65) demonstrated relatively
high release of IL-10, IL-8, IL-1β, and IL-6; low release
of IL-12p70, TNFα, and IP-10; and elevated level of
plasma IL-6. Cluster 3 (n = 115) showed relatively low
release of all cytokines after blood stimulation accom-
panied by the low level of plasma IL-6.
Kruskal-Wallis test followed by post-hoc characterization
supported our visual observations (Additional file 2: Table
S1). Cluster 1 had the highest release of IL-12p70 (p <
0.01), TNFα (p < 0.01), and IP-10 (p < 0.01) among all clus-
ters. Cluster 2 had higher release of IL-10 (p < 0.01), IL-8
(p < 0.01), and plasma level of IL-6 (p < 0.01) compared to
other clusters. Cluster 3 was characterized by the lowest re-
lease of IL-6 (p < 0.01), IL-1β (p < 0.01), and TNFα (p <
0.01) among clusters. There were no differences between
cluster 1 and 3 in the plasma level of IL-6 (p = 1.00) and re-
lease of IL-10 (p = 0.37) and IL-8 (p = 0.98).
The 3-month functional outcome differed between three
clusters. We observed the lowest rate of poor outcome in
cluster 1, the highest in cluster 2, and intermediate in clus-
ter 3 (25%, 69.2%, and 42.6%, respectively). When we used
cluster 1 as a reference, the risk of poor outcome was in-
creased 4.79-times (95%CI 2.13–10.78, p < 0.01) for cluster
2 and 2.14-times (95%CI 1.05–4.37, p = 0.04) for cluster 3
in the analysis adjusted for age and stroke severity.
Table 1 Comparison of baseline characteristics and levels of cytokines between good and poor outcome groups
Good outcome (mRS 0-2)
n = 137
Poor outcome (mRS 3-6)
n = 111
p value
Age, median (IQs) 66 (58–75) 72 (63–81) <0.01
Female, n (%) 53 (38.7) 49 (44.1) 0.75
Hypertension, n (%) 104 (75.9) 90 (81.1) 0.33
Diabetes mellitus, n (%) 35 (25.6) 35 (31.5) 0.30
Atrial fibrillation, n (%) 40 (29.2) 31 (27.9) 0.83
Myocardial infarction, n (%) 17 (12.4) 17 (15.3) 0.51
Previous stroke, n (%) 14 (10.2) 16 (14.4) 0.31
Current smoking, n (%) 37 (27.0) 27 (24.3) 0.63
NIHSS score on admission, median (IQs) 6 (4–13) 15 (7–19) <0.01
Thrombolysis, n (%) 77 (56.2) 61 (55.0) 0.84
Thrombectomy, n (%) 39 (28.5) 26 (23.4) 0.37
Etiology 0.17
Large vessel disease, n (%) 29 (21.2) 37 (33.3)
Small vessel disease, n (%) 9 (6.6) 4 (3.6)
Cardioembolic, n (%) 44 (32.1) 29 (26.1)
Undetermined, n (%) 49 (35.8) 39 (35.1)
Other, n (%) 6 (4.4) 2 (1.8)
Cytokines
Ex vivo stimulation
IL-12p70, pg/ml, median (IQs) 5.6 (1.7–11.0) 3.0 (0.0–5.2) <0.01
IL-10, pg/ml, median (IQs) 44.4 (32.0–69.3) 65.6 (40.4–89.4) <0.01
IL-6, pg/ml, median (IQs) 11611 (8279–16298) 11534 (8013–17757) 0.96
IL-1β, pg/ml, median (IQs) 1611 (1101–2313) 1323 (797–2095) 0.01
IL-8, pg/ml, median (IQs) 1528 (953–2276) 2256 (1237–3459) <0.01
TNFα, pg/ml, median (IQs) 2570 (1785–3793) 2071 (1518–2835) <0.01
IP-10, pg/ml, median (IQs) 474 (25–832) 288 (138–534) <0.01
Plasma
IL-6, pg/ml, median (IQs) 3.2 (1.9–6.5) 8.9 (4.6–25.2) <0.01
IQs interquartiles, NIHSS National Institutes of Health Stroke Scale
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Multimarker score
To construct multimarker score, we used four cytokines
that remained significantly associated with poor out-
come in the final backward elimination model: IL-12p70,
IL-10, TNFα, and plasma IL-6. Table 3 shows the β-
coefficients of included cytokines and predictive values
of multimarker score.
In the multivariate analysis adjusted for age and stroke
severity, patients with higher multimarker score had 2.72-
times per unit increased risk of worse outcome (95%CI
1.86–3.99, p < 0.01). After addition of multimarker score
to the best-fit clinical model, we observed improvement in
discrimination of poor outcome (Fig. 2), supported by the
increase in AUC (p = 0.02) and IDI (p < 0.01) (Table 3).
The model with the multimarker score was well-
calibrated (Hosmer-Lemeshow χ2 p = 0.98). Multimarker
score also performed better than each of cytokines added
to the best-fit clinical model (p < 0.05): IL-12p70 (AUC =
0.768), IL-10 (AUC = 0.750), IL-8 (AUC = 0.746), TNFα
(AUC = 0.750), IP-10 (AUC = 0.750), IL-1β (AUC =
0.741), and plasma IL-6 (AUC = 0.752).
In addition, multimarker score significantly improved
the classification accuracy for poor outcome compared
to the best-fit clinical model as evidenced by categorical
Table 2 Predictors of poor outcome identified in the univariate analysis and results of backward elimination models
Univariate analysis Multivariate analysis of individual cytokines adjusted
for age and stroke severity
Multivariate analysis of all cytokines adjusted for
age and stroke severity
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age 1.04 1.02–1.06 <0.01 1.04 1.02–1.06 <0.01 1.03 1.01–1.06 0.01
NIHSS on admission 1.12 1.07–1.16 <0.01 1.12 1.07–1.17 <0.01 1.09 1.04–1.14 <0.01
Cytokines*
Ex vivo stimulation
IL-12p70 0.46 0.31–0.67 <0.01 0.50 0.34–0.74 <0.01 0.55 0.36–0.84 <0.01
IL-10 1.55 1.17–2.05 <0.01 1.49 1.11–2.00 <0.01 1.83 1.32–2.56 <0.01
IL-1β 0.69 0.52–0.90 <0.01 0.74 0.55–0.99 0.04 0.85 0.60–1.20 0.36
IL-8 1.75 1.22–2.51 <0.01 1.54 1.06–2.22 0.02 1.28 0.80–2.05 0.31
TNFα 0.62 0.46–0.84 <0.01 0.67 0.49–0.92 0.01 0.64 0.44–0.92 0.02
IP-10 0.61 0.44–0.84 <0.01 0.65 0.47–0.90 0.01 0.89 0.59–1.34 0.58
Plasma
IL-6 2.68 1.64–4.39 <0.01 1.86 1.17–2.94 < 0.01 1.59 1.02–2.47 0.04
*Cytokines were standardized to the same scale (mean = 0; SD = 1)
NIHSS – National Institutes of Health Stroke Scale; OR- odds ratio; 95% CI- 95% confidence interval
Fig. 1 Results of cluster analysis. Y axis: median z-scores of eight clustered cytokines. Error bars represent interquartiles. X axis: clusters.
IL—interleukin; IP-10—interferon-gamma-inducible protein 10; TNFα—tumor necrosis factor alpha
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NRI (0.249, p < 0.01) and continuous NRI (0.672, p <
0.01). Reclassification tables are shown in Additional file
3: Table S2. Among patients with poor outcome, 18.0%
(n = 20) were correctly upclassified versus 6.3% (n = 7)
incorrectly downclassified. In the good outcome group
21.9% (n = 30) were correctly downclassified whereas
8.8% (n = 12) were incorrectly upclassified by multimar-
ker score.
Discussion
Our study showed that ex vivo cytokine synthesis after
whole blood stimulation with LPS differs between stroke
patients with good outcome and patients with poor out-
come. We found that the decreased release of TNFα, IL-
1β, IP-10, and IL-12 and the increased release of IL-10
and IL-8 are associated with poor functional outcome.
Emsley et al. studied ex vivo cytokine synthesis in 36
acute ischemic stroke patients [8]. They found the de-
creased TNFα, IL-1β, and IL-6 production after in vitro
blood stimulation in non-survivors and patients with
poor functional outcome. Recently, we reported that the
reduced release of TNFα and IP-10 is independently
from age and stroke severity associated with worse prog-
nosis after stroke [9].
The current study provides a new piece of information
about a relationship between ex vivo synthesized cyto-
kines and stroke outcome. It demonstrates the decreased
production of IL-12 and increased release of IL-10 and
IL-8 in patients with unfavorable prognosis. Interleukin-
12 is a pro-inflammatory cytokine that plays a key role
in resistance to infections by modulating the activity of
natural killer cells and T cells [25]. Interleukin-10 is a
prototypic anti-inflammatory cytokine that limits the im-
mune response to pathogens [26]. In stroke patients,
higher plasma level of IL-10 is associated with the in-
creased risk of infections [27] and lack of response to
preventive antibacterial therapy [28]. Thus, the de-
creased IL-12 and increased IL-10 release from blood
cells might contribute to post-stroke immunodepression.
Interleukin-8 is a chemokine involved in the recruit-
ment and activation of neutrophils [29]. Neutrophils play
Table 3 Multimarker score and prediction of poor outcome
Poor outcome p value
Cytokines included in the score*
IL-12p70, Coef (95%CI) − 0.60 (− 1.03 to − 0.17) <0.01
IL-10, Coef (95%CI) 0.61 (0.27–0.94) <0.01
TNFα, Coef (95%CI) − 0.45 (− 0.82 to − 0.08) 0.02
Plasma IL-6, Coef (95%CI) 0.46 (0.02–0.90) 0.04
Score, per 1- unit increment
Unadjusted OR (95%CI) 3.24 (2.22–4.73) <0.01
Adjusted† OR (95%CI) 2.72 (1.86–3.99) <0.01
c Statistics
Best-fit clinical model, AUC (95%CI) 0.731 (0.668–0.794) 0.02
Best-fit clinical model + multimarker score, AUC (95%CI) 0.808 (0.755–0.861)
IDI (95%CI) 0.125 (0.084–0.167) <0.01
Continuous NRI (95%CI) 0.672 (0.437–0.907) <0.01
Categorical NRI (95%CI) 0.249 (0.122–0.375) <0.01
IDI integrated discrimination improvement, NRI net reclassification improvement
*Levels of cytokines were standardized to the same scale (mean = 0, SD = 1)
†Analysis adjusted for age and stroke severity on admission
Fig. 2 Receiver operating characteristics. Black line represents the
performance of the best-fit clinical model to discriminate patients
with poor outcome. Gray line shows the performance of the
enhanced model after addition of multimarker score
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an important role in ischemic brain injury [30]. Exces-
sive neutrophil activation by IL-8 could contribute to
greater brain damage after stroke and consequently leads
to worse outcome.
Consistently with previous reports, we also observed
the elevated level of circulating IL-6 in patients with
poor outcome [6, 7].
We did not find any association between ex vivo syn-
thesized IL-6 and functional outcome. Emsley et al. re-
ported the correlation between the reduced IL-6
production and worse outcome after stroke [8]. This dis-
crepancy between studies could be explained by several
methodological differences including the sample size,
the method of blood stimulation, and statistical ap-
proach. First, Emsley et al. measured cytokine produc-
tion at several timepoints in the first week after stroke.
Only minimal cytokine production was used to assess a
correlation between cytokine synthesis and outcome.
Second, Emsley et al. used much higher dose of LPS to
stimulate blood cells (200 ng/mL vs 10 ng/mL). Third,
the sample size differs between these two studies (36 vs
248 patients). Finally, we dichotomized outcome score
and performed uni- and multivariate logistic regression
analysis, whereas Emsley et al. correlated cytokine level
with the mRS score.
Cluster analysis revealed interactions between synthesized
cytokines, plasma IL-6, and stroke outcome. We identified
three groups of patients with distinct cytokine profiles. The
group with the worst outcome demonstrated relatively high
synthesis of IL-10, IL-8, IL-1β, and IL-6 and low synthesis
of IL-12, IP-10, and TNFα accompanied by high circulating
IL-6 level. The group with the best prognosis showed rela-
tively high synthesis of TNFα, IP-10, IL-12, IL-1β, and IL-6
together with low synthesis of IL-10 and IL-8. Plasma level
of IL-6 was relatively low in this group. Patients with inter-
mediate outcome had relatively low synthesis of all cyto-
kines accompanied by low circulating IL-6. Our findings
suggest that stroke outcome may depend on the interplay
between stroke-induced immunodepression and systemic
inflammation. The relatively low production of pro-
inflammatory cytokines was associated with comparatively
good outcome if immunodepression was not accompanied
by systemic inflammation (low circulating IL-6). In experi-
mental models of stroke, systemic inflammation is linked to
poor outcome via permanent disruption of the blood-brain
barrier, neutrophil mobilization and infiltration into the is-
chemic brain, impaired reperfusion, and enhanced platelet
activity [10]. Immunodepression may worsen outcome by
increasing the incidence of systemic infections [1]. Our
cluster analysis also underlines the association between
ex vivo IL-10 and IL-8 production and outcome. In con-
trast to patients with the best and intermediate prognosis,
patients with the worst outcome had high synthesis of these
cytokines.
Although observational studies are not able to demon-
strate a causative relationship between cytokine synthesis
and stroke outcome, both systemic inflammation and
immunodepression could be considered as a potential
therapeutic target. Agents that target components of IL-
6 signaling pathway (e.g., monoclonal antibodies against
IL-6 or IL-6 receptor or Janus kinases inhibitors) might
attenuate systemic inflammation [31]. In healthy men
volunteers who received endotoxin intravenously, immu-
nodepression was partially reversed by subcutaneous ad-
ministration of interferon-ɣ [32]. This treatment
increased ex vivo LPS-induced TNFα release. In vitro β-
glucan, a component of Candida albicans, partially re-
versed the LPS-induced immunodepression [33]. Ex vivo
β-glucan treatment of monocytes from volunteers re-
ceiving LPS injection re-instanced their capacity for
cytokine synthesis [31]. Of note, it remains unclear if re-
version of post-stroke immunodepression will result in
better outcome.
The accurate prediction of outcome after stroke is im-
portant in clinical practice. Biomarkers may facilitate
stroke prognosis. Whiteley and colleagues proposed de-
sirable features of a biomarker for stroke prognosis: (1)
independent association of with outcome, (2) statistically
significant predictive value added to a clinical model,
and (3) improvement of the patients’ classification [22].
Blood-derived inflammatory biomarkers might provide
useful information to improve prediction of outcome
after stroke [34]. In the second part of our study, we
assessed the prognostic value of cytokine-based multi-
marker score. Our multimarker score included ex vivo
synthesized IL-12, IL-10, TNFα, and plasma IL-6. This
multimarker score was independently associated with
outcome after adjusting for the two most important
stroke prognosticators: age and stroke severity. The
addition of this score to the clinical model improved dis-
crimination and reclassification. The multimarker score
provided greater improvement in outcome prediction
than individual cytokines. Although direct comparison
between studies is difficult due to different methodolo-
gies, our multimarker score combining synthetized cyto-
kines and plasma IL-6 seems to have better predictive
value than other inflammatory markers including circu-
lating IL-6, C-reactive protein, or fibrinogen [6, 7, 22,
35]. Given our results, it would be interesting to investi-
gate in future studies the predictive ability of combin-
ation of ex vivo synthesized cytokines with other
circulating inflammatory markers such as C-reactive
protein or fibrinogen.
We need to address several limitations of our study. First,
our results need confirmation in an independent popula-
tion. Second, we performed whole blood stimulation 3 days
after stroke. The prognostic value of our biomarkers mea-
sured early after stroke onset needs to be determined.
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Third, there are no widely acceptable thresholds to calcu-
late category-based NRI. Similar to previous studies [7, 35],
we applied stringent thresholds which are relevant for
stroke clinical practice. Less rigorous thresholds could pro-
vide different results. Therefore, an optimal value of thresh-
olds should be further tested in future studies.
We are aware that our novel biomarker is not ready
for use in daily clinical practice. The necessity of blood
culture in appropriate laboratory conditions strongly
limits the technical feasibility of our biomarker. How-
ever, commercially available tubes with cell culture
media and immune stimulant may offer a practical solu-
tion to monitoring cytokine synthesis without specialized
technical experience [36]. They allow performing blood
stimulation in room air using a heating block. Minimal
sample handling and low amount of blood needed for
stimulation are other advantages which may facilitate
wider use of whole blood stimulation in clinics. It would
be interesting to assess in future studies the combination
of the cytokine-based composite biomarker with other
non-inflammatory biomarkers (e.g., copeptin).
Conclusions
In conclusion, the decreased release of some pro-
inflammatory cytokines (IP-10, TNFα, IL-1β, and IL-
12p70) and increased release of IL-10 and IL-8 after
ex vivo blood stimulation with LPS are related to poor
outcome after stroke. This association is modulated by
plasma IL-6. Cytokine-based multimarker score com-
posed of ex vivo released IL-12, IL-10, TNFα, and
plasma IL-6 adds prognostic value to clinical model for
predicting stroke outcome.
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